Research published in JAMA suggests that suboptimal intake of specific dietary factors is associated with almost half of deaths from heart disease, stroke, or type 2 diabetes in the USA.
A meta-analysis published in JAMA shows that mutations linked to reduced low-density lipoprotein cholesterol levels are associated with an increased risk of diabetes.
Nonstatin therapies that act via upregulation of the low-density lipoprotein receptor prevent major vascular events as effectively as statins do, shows an analysis in JAMA.
Proprotein convertase subtilisin/kexin type 9 inhibitors are not currently cost effective for the prevention of cardiovascular events in patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, US research shows.
There is insufficient evidence to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents, concludes a recommendation statement from the US Preventive Services Task Force.
Pooled data from the ODYSSEY phase III trials show that PCSK9 inhibition does not result in excess cases of new-onset diabetes during up to 18 months of treatment, despite mounting evidence that lowering cholesterol levels increases diabetes risk.
Findings from a Mendelian randomisation study suggest that lifelong exposure to increased levels of the major lipid fractions is protective against Type 2 diabetes, even as it raises the risk of coronary artery disease.
Patients with acute coronary syndromes have a more than doubled risk of recurrent coronary events within the subsequent year if they meet clinical criteria for familial hypercholesterolaemia, research shows.
The benefits of statin-based treatments among patients with chronic kidney disease diminish with decreasing estimated glomerular filtration rate, with little evidence of any benefit for patients on dialysis, results of a large meta-analysis show.
A retrospective analysis suggests that statin therapy reduces the risk of a first coronary artery disease event or death in patients with familial hypercholesterolaemia by around 44%.
Patients with levels of low-density lipoprotein cholesterol normally seen in familial hypercholesterolaemia have the cardiovascular risk of someone decades older than they are, shows a population-based study.
Patients treated for hypercholesterolaemia in clinical practice may not derive additional benefit from very intensive statin treatment, say researchers.
People who have dyslipidemia or are overweight adopt healthier diets than those without, whereas patients with hypertension persist with some unhealthy eating patterns, study results show.
Researchers have found that users of the obesity drug, orlistat, have an increased risk for acute liver injury compared with non-users in the time period prior to taking the drug.
The factors that influence compliance with statin therapy are complex, with high rates of statin discontinuation yet also high long-term tolerance when rechallenged, shows research.